224 related articles for article (PubMed ID: 21182431)
21. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial.
Kyvernitakis I; Kann PH; Thomasius F; Hars O; Hadji P
Bone; 2018 Sep; 114():109-115. PubMed ID: 29908297
[TBL] [Abstract][Full Text] [Related]
22. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
Brufsky AM
Clin Breast Cancer; 2007 Dec; 8 Suppl 1():S22-34. PubMed ID: 18282367
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
Logman JFS; Heeg BMS; Botteman MF; Kaura S; van Hout BA
Ann Oncol; 2010 Jul; 21(7):1529-1536. PubMed ID: 19955334
[TBL] [Abstract][Full Text] [Related]
24. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Safra T; Bernstein-Molho R; Greenberg J; Pelles-Avraham S; Stephansky I; Sarid D; Inbar MJ; Stemmer SM; Geffen DB
Oncology; 2011; 81(5-6):298-305. PubMed ID: 22156381
[TBL] [Abstract][Full Text] [Related]
25. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
Søe K; Plesner T; Jakobsen EH; Hansen CT; Jørgensen HB; Delaissé JM
J Bone Miner Res; 2013 Aug; 28(8):1738-50. PubMed ID: 23427025
[TBL] [Abstract][Full Text] [Related]
26. A prospective randomized controlled clinical trial of zoledronic acid for bone metastases.
Mystakidou K; Katsouda E; Parpa E; Kouskouni E; Chondros C; Tsiatas ML; Galanos A; Vlahos L
Am J Hosp Palliat Care; 2006; 23(1):41-50. PubMed ID: 16450662
[TBL] [Abstract][Full Text] [Related]
27. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
29. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
30. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
31. Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Kann P
Breast Cancer Res Treat; 2014 Apr; 144(2):343-51. PubMed ID: 24519387
[TBL] [Abstract][Full Text] [Related]
32. A clinician's perspective on the use of zoledronic acid in the treatment of postmenopausal osteoporosis.
Lewiecki EM
J Clin Densitom; 2008; 11(4):478-84. PubMed ID: 18757222
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.
Botteman MF; Meijboom M; Foley I; Stephens JM; Chen YM; Kaura S
Eur J Health Econ; 2011 Dec; 12(6):575-88. PubMed ID: 20809091
[TBL] [Abstract][Full Text] [Related]
34. Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats.
Khajuria DK; Razdan R; Mahapatra DR
J Orthop Sci; 2014 Jul; 19(4):646-56. PubMed ID: 24668309
[TBL] [Abstract][Full Text] [Related]
35. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
Ottewell PD; Wang N; Brown HK; Reeves KJ; Fowles CA; Croucher PI; Eaton CL; Holen I
Clin Cancer Res; 2014 Jun; 20(11):2922-32. PubMed ID: 24687923
[TBL] [Abstract][Full Text] [Related]
36. Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
Søe K; Delaissé JM; Jakobsen EH; Hansen CT; Plesner T
Acta Oncol; 2014 Apr; 53(4):547-56. PubMed ID: 24164102
[TBL] [Abstract][Full Text] [Related]
37. Zoledronate effects on systemic and jaw osteopenias in ovariectomized periostin-deficient mice.
Bonnet N; Lesclous P; Saffar JL; Ferrari S
PLoS One; 2013; 8(3):e58726. PubMed ID: 23505553
[TBL] [Abstract][Full Text] [Related]
38. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Lipton A
Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
[TBL] [Abstract][Full Text] [Related]
39. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
40. Zoledronic acid use in cancer patients: more than just supportive care?
Coleman R; Cook R; Hirsh V; Major P; Lipton A
Cancer; 2011 Jan; 117(1):11-23. PubMed ID: 21235033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]